Allogeneic Stem Cell Therapy in Heart Failure

Inclusion Criteria: 1. 30 to 80 years of age 2. Signed informed consent 3. Chronic stable ischemic heart disease 4. Symptomatic heart failure - New York Heart Association (NYHA) class II-III 5. EF ≤45% 6. Plasma NT-pro-BNP \> 300 pg/ml (\> 35 pmol/L) in sinus rhythm and plasma NT-pro-BNP \> 422 pg/ml (\> 450 pmol/L) in patients with atrial fibrillation 7. Maximal tolerable heart failure medication 8. Medication unchanged two months prior to inclusion 9. No option for percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) 10. Patients who have had PCI or CABG within six months of inclusion must have a new angiography less than one month before inclusion or at least four months after the intervention to rule out early restenosis 11. Patients cannot be included until three months after implantation of a cardiac resynchronisation therapy device Exclusion Criteria: 1. Heart Failure (NYHA I or IV) 2. Acute coronary syndrome with elevation of creatine kinase (CK) isoenzyme MB (CKMB) or troponins, stroke or transitory cerebral ischemia within six weeks of inclusion 3. Other revascularisation treatment within four months of treatment 4. If clinically indicated the patient should have a coronary angiography before inclusion 5. Moderate to severe aortic stenosis (valve area \< 1.3 mm2) or valvular disease with option for surgery. 6. Diminished functional capacity for other reasons such as: obstructive pulmonary disease (COPD) with forced expiratory volume (FEV) \<1 L/min, moderate to severe claudication or morbid obesity 7. Clinical significant anaemia (haemoglobin \< 6 mmol/L), leukopenia (leucocytes \< 2 109/L), leucocytosis (leucocytes \>14 109/L) or thrombocytopenia (thrombocytes \< 50 109/L) 8. Anticoagulation treatment that cannot be paused during cell injections 9. Patients with reduced immune response 10. History with malignant disease within five years of inclusion or suspected malignity - except treated skin cancer other than melanoma 11. Pregnant women 12. Other experimental treatment within four weeks of baseline tests 13. Participation in another intervention trial